Advertisement
Product › Details
cisplatin
Next higher product group | chemotherapeutic | |
Status | 2007-11-21 development existent | |
Record changed: 2023-07-10 |
Advertisement
More documents for chemotherapeutic
- [1] Heraeus. (8/10/21). "Press Release: Heraeus Expands Capacity for Platinum-based Active Pharmaceutical Ingredients to Treat Cancer". Hanau....
- [2] Roche. (3/19/19). "Press Release: FDA Approves Roche’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-stage Small Cell Lung Cancer". Basel....
- [3] 4SC AG. (9/20/18). "Press Release: Domatinostat Plus Chemotherapy – Overcoming Drug Resistance". Planegg-Martinsried....
- [4] AstraZeneca plc. (5/8/18). "Press Release: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-sensitive Relapsed Ovarian Cancer"....
- [5] AstraZeneca plc. (2/23/18). "Press Release: Lynparza Receives Positive EU CHMP Opinion in Platinum-sensitive Relapsed Ovarian Cancer"....
- [6] Merck & Co., Inc.. (9/5/17). "Press Release: European Commission Approves Merck’s Keytruda (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer". Kenilworth, NJ....
- [7] AstraZeneca plc. (8/17/17). "Press Release: Lynparza Receives Additional and Broad Approval in the US for Ovarian Cancer"....
- [8] Helsinn Healthcare S.A.. (6/12/17). "Press Release: Zealand to Regain Control of Elsiglutide. Helsinn Returns Elsiglutide to Zealand". Lugano & Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top